Skip to main content
. 2020 Nov 13;10:541262. doi: 10.3389/fonc.2020.541262

Figure 3.

Figure 3

MTA1 knockdown with gemcitabine treatment up regulated the ros-reaction and apoptosis in MCF-7 cells. (1) breast cancer cells (NC_MCF-7 or shMTA1_MCF-7) are planted in 24-well plates for 24h, followed by 48h-treatment of 5μM gemcitabine or DMSO (4 groups: NC_DMSO, NC_GEM, shMTA1_DMSO and shMTA1_GEM), which are tested for live-death assay (live: green, death: red) (A, D). (2) breast cancer cells (MCF-7 or shMTA1_MCF-7) are planted in 24-well plates for 24h, followed by 48h-treatment of 5μM gemcitabine or DMSO (4 groups: NC_DMSO, NC_GEM, shMTA1_DMSO and shMTA1_GEM), which are tested for ros-reaction through ros probes (ros: green, DAPI: blue) (B, E). (3) breast cancer cells (MCF-7 or shMTA1_MCF-7) are planted in 6-well plates for 24h, followed by 48h-treatment of 5μM gemcitabine or DMSO (i: NC_DMSO, ii: NC_GEM, iii: shMTA1_DMSO, iv: shMTA1_ GEM), which are tested for apoptosis and WB assay (C, F–M).